RESEARCH into early-onset colorectal cancer (CRC) has found unique subgroups among younger patients and has outlined risk factors and prevalence of…

Obesity is a known risk factor for a multitude of cancers, including pancreatic, ovarian, and liver, and contributes to an estimated 15–20% of all cancer…

ANDROGEN deprivation therapy (ADT) is commonly used for the treatment of metastatic hormone sensitive prostate cancer (mHSPC)…

KIDNEY STONES are a painful affliction that are common in the general population, with their prevalence estimated to be 1 in 11 in the USA population…

BILIARY atresia (BA) is a hepatic condition in which bile ducts within and surrounding the liver are abnormally narrow, impeded, or missing…

BIOMARKERS of fatty liver disease have been discovered by a group of researchers from the University of California, California, USA and…

Karsten Lollike is the Corporate Vice President and the Qualified Person Responsible for Pharmacovigilance (QPPV) of Global Safety at Novo Nordisk, a position he has held for 11 years. Dr. Lollike joined Novo Nordisk in 2000, working in Global Development in Haemostasis, after obtaining his medical degree and subsequently a PhD. We spoke to Dr. Lollike about his medical expertise and experience, his long-standing career at Novo Nordisk, and what working at the company means to him.

IMMUNE rejection is one of the most serious risks of organ transplantation, an increasingly common procedure that is granting patients across the world…

Calcium signalling is essential for inter and intra-cellular neuronal communication, and efforts for improving its imaging are constantly ongoing…

UNDERSTANDABLE optimism surrounds nanoparticle technology and its application for the treatment of diseases such as cancer…